



**5th Translational Research Conference
Multiple Myeloma**

October 8-11, 2020

Chairpersons : Kenneth C. Anderson, Maria-Victoria Mateos, Philippe Moreau

Thursday, October 8th, 2020

14:00–14:15 Welcome

SESSION I – Smoldering myeloma

Chair: TBA

14:15-14:20	Introduction	Session chair
14:20-14:35	Clonal evolution in smoldering myeloma	Madhav V. Dhodapkar (Atlanta)
14:35-14:50	High-risk smoldering : what is the exact definition ?	Irene Ghobrial (Boston)
14:50-15:05	Clinical trials	Maria-Victoria Mateos (Salamanca)
15:05-15:12	Selected brief oral communication	
15:12-15:40	<i>Panel discussion</i>	
15:40-15:50	<i>Coffee Break</i>	

SESSION II – Diagnosis of multiple myeloma

Chair: TBA

15:50-15:55	Introduction	Session Chair
15:55-16:10	Diagnostic criteria and initial workup	Shaji Kumar (Rochester)
16:10-16:25	Genetics and risk assessment	Hervé Avet-Loiseau (Toulouse)
16:25-16:40	Frailty assessment at diagnosis	Alessandra Larocca (Turin)
16:40-16:47	Selected brief oral communication	Speaker
16:47-17:15	<i>Panel discussion</i>	
17:25	Mentored Poster Walks	

13:20-14:20 Possible slot for a satellite symposium

SESSION III – Frontline therapy in patients not eligible for autologous stem cell transplantation

Chair: TBA

14:25-14:30	Introduction	Session chair
14:30-14:45	Overview phase 3 trials and newly approved treatments	Xavier Leleu (Lille)
14:45-15:00	Fit vs Frail: the European point of view	Sonja Zweegman (Amsterdam)
15:00-15:15	Fit vs frail: The point of view of North America	Hira Mian (Hamilton)
15:15-15:22	Selected brief oral communication	Speaker
15:22-15:50	<i>Panel discussion</i>	
15:50-16:00	<i>Coffee break</i>	

SESSION IV – Frontline therapy in patients eligible for autologous stem cell transplantation

Chair: TBA

16:00-16:05	Introduction	Session chair
16:05-16:20	Overview of European trials	Philippe Moreau (Nantes)
16:20-16:35	US point of view on new trials (including explanation of why HSCT is not proposed frontline)	Paul Richardson (Boston)
16:35-16:50	Maintenance therapy	Graham Jackson (Newcastle)
16:50-16:57	Selected brief oral communication	Speaker
16:57-17:25	<i>Panel discussion and/or controversial debates</i>	

17:30-18:30 3 Simultaneous Meet the Expert sessions

- | | |
|---|-----|
| 1. Assessments for MRD evaluation | TBA |
| 2. Definition and identification of high-risk Myeloma | TBA |
| 3. Immunoprofiling in Myeloma | TBA |

09:30-10:30 Possible slot for a satellite symposium

SESSION V – MRD and the microenvironment

Chair: TBA

10:35-10:40	Introduction	Session chair
10:40-10:55	MRD and imaging	Elena Zamagni (Bologna)
10:55-11:10	MRD and immune profiling (differences in terms of response)	Bruno Paiva (Pamplona)
11:10-11:25	How MRD assessment will impact clinical management	Noemi Puig (Salamanca)
11:25-11:32	Selected brief oral communication	Speaker
11:32-12:00	<i>Panel discussion</i>	

12:00-13:40 Lunch

12:30-13:30 Possible slot for a satellite symposium

SESSION VI – Relapsed multiple myeloma

Chair: TBA

13:40-13:45	Introduction	Session chair
13:45-14:00	How to sequence in 1 st and 2nd relapse?	Meletios Dimopoulos (Athens)
14:00-14:15	Beyond 2 nd relapse	Saad Usmani (Charlotte)
14:15-14:30	Overview immune therapies?	Noopur Raje (Boston)
14:30-14:37	Brief Oral Communication	Speaker
14:37-15:05	<i>Panel discussion</i>	

SESSION VII – The future: recent clinical trials in relapse

Chair: TBA

15:05-15:10	Introduction	Session chair
15:10-15:25	Novel targeted therapies (not immune)	Shaji Kumar (Rochester)
15:25-15:40	Novel immunotherapies (part 1)	Hermann Einsele (Würzburg)
15:40-15:55	Novel immunotherapies (part 2)	Sagar Lonial (Atlanta)

Draft VIRTUAL 08/07/2020

15:55-16:02 **Brief Oral Communication** Speaker

16:02-16:25 *Panel discussion and/or controversial debates*

16:25-16:35 Coffee break

16:35-17:35 4 Simultaneous Breakfast Meet the Expert

- | | |
|--|-----|
| 1. Management of MM patients Len-refractory | TBA |
| 2. How are we going to select the ideal MM patient for CAR-T? | TBA |
| 3. Are there new targets in Myeloma beyond CD38? | TBA |
| 4. Therapeutic strategies targeting the tumor microenvironment | TBA |

Sunday, October 11th, 2020

10:15-11:15 Possible slot for a satellite symposium

SESSION VIII – Data management issues

Chair: TBA

- | | | |
|--------------------|---|----------------------------------|
| 11:20-11:25 | Introduction | Session chair |
| 11:25-11:40 | Access to innovative drugs: pharma-academia cooperation | Mohamad Mohty (Paris) |
| 11:40-11:55 | iStopMM-a nationwide screening for MGUS and myeloma and early treatment of smoldering myeloma | Sigurdur Kristinsson (Reykjavik) |
| 11:55-12:10 | Bureaucracy is strangling clinical research | Steven Le Gouill (Nantes) |
| 12:10-12:25 | EMA vs FDA approvals: differences, why ? | Kyriaki Tzogani (Amsterdam) |
| 12:25-12-32 | Brief Oral Communication | Speaker |
| 12:32-13:00 | <i>Panel discussion</i> | |
| 13:00-13:55 | Lunch | |

SESSION IX – Plasma cell disorders

Chair: TBA

- | | | |
|-------------|--|---------------------------|
| 13:55-14:00 | Introduction | Session chair |
| 14:00-14:15 | Waldenstrom's disease | Jorge Castillo (Boston) |
| 14:15-14:30 | POEMS | Arnaud Jaccard (Limoges) |
| 14:30-14:45 | Monoclonal gammopathy of clinical significance | Jean-Paul Fermand (Paris) |

Draft VIRTUAL 08/07/2020

14:45-15:00 Amyloidosis

Giampaolo Merlini (Pavia)

15:00-15:05 **Brief Oral Communication**

Speaker

15:05-15:35 *Panel discussion*

MEETING CLOSURE